IPO Year: 2024
Exchange: AMEX
| Date | Price Target | Rating | Analyst |
|---|
4 - Chromocell Therapeutics Corp (0001919246) (Issuer)
4 - Chromocell Therapeutics Corp (0001919246) (Issuer)
4 - Chromocell Therapeutics Corp (0001919246) (Issuer)
4/A - Chromocell Therapeutics Corp (0001919246) (Issuer)
DEFM14C - Channel Therapeutics Corp (0001919246) (Filer)
10-Q - Channel Therapeutics Corp (0001919246) (Filer)
PREM14C - Channel Therapeutics Corp (0001919246) (Filer)
8-K - Channel Therapeutics Corp (0001919246) (Filer)
8-K - Channel Therapeutics Corp (0001919246) (Filer)
10-K - Channel Therapeutics Corp (0001919246) (Filer)
8-K - Channel Therapeutics Corp (0001919246) (Filer)
SCHEDULE 13G - Channel Therapeutics Corp (0001919246) (Subject)
EFFECT - Channel Therapeutics Corp (0001919246) (Filer)
POS AM - Channel Therapeutics Corp (0001919246) (Filer)
4 - Channel Therapeutics Corp (0001919246) (Issuer)
4 - Channel Therapeutics Corp (0001919246) (Issuer)
4 - Chromocell Therapeutics Corp (0001919246) (Issuer)
4 - Chromocell Therapeutics Corp (0001919246) (Issuer)
4 - Chromocell Therapeutics Corp (0001919246) (Issuer)
4 - Chromocell Therapeutics Corp (0001919246) (Issuer)
4 - Chromocell Therapeutics Corp (0001919246) (Issuer)
4 - Chromocell Therapeutics Corp (0001919246) (Issuer)
4 - Chromocell Therapeutics Corp (0001919246) (Issuer)
3/A - Chromocell Therapeutics Corp (0001919246) (Issuer)
FREEHOLD, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has achieved its predefined endpoints in two pre-clinical animal models of the Company's eye drop formulations ("CT2000") for the treatment of both acute ocular pain as well as chronic ocular surface pain commonly associated with dry eye disease. "We are very pleased with the results of these animal efficacy studies, which adds to the Depot formulation study results announced in December 2024, demonstrating a viable path forward in treating both post-surgical pain and ch
FREEHOLD, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today advises that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March 27, 2025, the audited financial statements contained an audit opinion from its independent registered public accounting firm that included a going concern emphasis of matter paragraph. Release of this information is required by Sections 410(h) and 610(b) of the NYSE American LLC Company Guide. This announcement does not rep
Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI™ ZELSUVMI is an FDA-designated novel drug and the first and only prescription medication approved for the treatment of Molluscum contagiosum infections administered at home by parents, patients, and caregivers Ligand is entitled to a 13% royalty on worldwide sales of ZELSUVMI Transaction is expected to close in the summer of 2025 JUPITER, Fla. and FREEHOLD, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated ("Ligand") (NASDAQ:LGND) and Channel Therapeutics Corporation ("Channel") (NYSE:CHRO), a pioneer i
FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, is providing a statement regarding Vertex Pharmaceutical's recently announced Phase 2 data of Suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy. "We are encouraged to see that the product will advance to Phase 3 trials in painful lumbosacral radiculopathy, pending discussions with regulators," said Eric Lang, Channel's Chief Medical Officer. "While both NaV1.7 and NaV1.8 are voltage-gated sodium channels mainly
FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it achieved its endpoints in two pre-clinical in vivo models of the Company's nerve block formulations for acute pain, showing material improvement over the existing standard of care, bupivacaine, in both efficacy and duration. "We are very pleased with the results, which potentially demonstrate that nerve blocks with our NaV1.7 inhibitors may be viable options for the treatment of acute and postoperative pain," stated Dr. Eric Lang, Chief Medical Officer of Channel. "Addi
"Channel Therapeutics" reflects the Company's focus on developing therapeutics to treat pain utilizing sodium channel blockade and modulationNew name is in advance of multiple near-term data readouts FREEHOLD, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation, (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that on November 18, 2024 it had changed its name to Channel Therapeutics Corporation ("Channel" or the "Company"), along with reincorporating in the State of Nevada. The Company believes the name change better reflects its focus on developing therapeutics based on sodium channel modulation and blockade for
FREEHOLD, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced the unveiling of its injectable depot program utilizing peripheral nerve blocks for the treatment of post-operative pain. The depot program is based on the Company's novel NaV1.7 molecule for treating chronic pain and eye pain. There are approximately 700,000 total knee replacements and 500,000 shoulder arthroplasties performed annually in the Unites States for which this analgesic modality might be applicable, providing a robust potential market for the product. "We are
FREEHOLD, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that Frank Knuettel II, CEO, will present at the upcoming LDMicro and Spartan Capital investor conferences. Details for the conferences and presentations are as follows: LDMicro Main Event XVII (October 28-30, 2024) Presentation: October 29, 2024 Time: 10:00 AM - 10:25 AM PTLocation: Luxe Sunset BLVD Hotel, Los AngelesIn-person registration: LINKVirtual attendance: LINKAvailable for 1x1 meetings: October 29th The Main Event has become the industry stand
FREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors (the "Board of Directors") has authorized an amendment (the "Amendment") to the Company's existing stock repurchase plan (as amended, the "Repurchase Plan") to increase the total value of shares of Chromocell's common stock ("Common Stock") available for repurchase by the Company under the Repurchase Plan by an additional $500,000, to $750,000. In addition, the Amendment extends the termination date of the Repurchase Plan from December 31, 20
Chromocell invites individuals, institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com FREEHOLD, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that Frank Knuettel, CEO, will present live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, on September 19th 2024. DATE: September 19th TIME: 11:00 AM ETLINK: https://bit.ly/3XjDJkLAvailable for 1x1 meetings: September 19th and September 20th This will be a live, interactive online event where inve
SC 13G/A - Chromocell Therapeutics Corp (0001919246) (Subject)
SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)
SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)
SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)
SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)
SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)
SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)
SC 13D - Chromocell Therapeutics Corp (0001919246) (Subject)